TechBio ๐พ Latest News & Update
TechBio ๐พ Latest News & Update
GreenStone Biosciences Inc, Cellares Corp, Spaero Bio, Sakana AI Labs, Superbio AI Inc and CDDVault ๐พ๐โ๏ธ
"โฆabout our origins, our destiny, and our place in the universe. We have no right to expect answers; we have no right to even ask. But ask and wonder we do. Human Universe is first and foremost a love letter to humanity; a celebration of our outrageous fortune."
By Brian Cox (Human Universe)
Latest News ๐ฅ
๐ข AI in Drug Discovery Market: $0.9B to $4.9B Growth Forecast (2023-2028) | Markets and Marketsโข
๐ฉ QuEra, Quantum Intelligence Team on Quantum Drug Discovery
๐ฅฆ Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform
๐ฅฌ Actuate Therapeutics (a Lantern Pharma Collaborator) Announces Pricing of Initial Public Offering
๐ InSilico Medicine Launches Open-Source AI Tool, Secure On-Site Omics Analysis Device
๐ Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable
๐ฑ AI in Healthcare: Improving Patient Outcomes and Operational Efficiency
๐ AI In Healthcare: Revolutionizing Medicine Or Overhyped Promise? By Bernard Marr
๐ข Digital health startup iLoF leverages AI and photonics platform to accelerate personalized drug development
GreenStone Biosciences Inc
GreenStone Biosciences (2021, US) combines cutting-edge technology with AI, computational biology and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. By harnessing the power of human (from both healthy individuals and those affected by various diseases) induced Pluripotent Stem Cells (hiPSC) collections and their advanced technologies (ADMET-AI), they offer a comprehensive platform for disease modeling, uncovering novel mechanisms and advancing drug discovery enabling the development of personalized treatment strategies (ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries).
ADMET-AI, is a ML platform that provides fast and accurate ADMET predictions both as a website and as a Python package: at admet.ai.greenstonebio.com and at github.com/swansonk14/admet_ai (also archived on Zenodo at doi.org/10.5281/zenodo.10372930). All data and models are archived on Zenodo at doi.org/10.5281/zenodo.10372418.
ADMET-AI has the highest average rank on the TDC ADMET Leaderboard, and it is currently the fastest web-based ADMET predictor, with a 45% reduction in time compared to the next fastest public ADMET web server. ADMET-AI can also be run locally with predictions for one million molecules taking just 3.1โh.
GreenStone, situated at Stanford Research Park within the Alexandria Center for Life Sciences, offers its iPSCs collections to academic investigators free of cost, fostering an environment of shared knowledge and progress.
On May 31, 2023, Creative Medical Technology Holdings, Inc (NASDAQ: CELZ), focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology and orthopedics, announced that it has received confirmation that Greenstone Biosciences has successfully developed a human induced pluripotent stem cell (iPSC) pipeline for the company's ImmCelz platform (Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelzยฎ Immunotherapy Platform). ImmCelz utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells.ย The collaboration with Greenstone Biosciences on this project is called the iPScelzย program, in order to increase the scalability for the ImmCelz Immunotherapy Platform at a lower cost and continue its drug discovery program using AI, and started back in June 2022.
Currently at GreenStone they are working on two drug candidates: GSB D100 for fibrotic indications (IND enabling) and GSB D300 for inflammatory indications (IND enabling).
GreenStone Biosciences has raised a total of $14.3M in funding over 3 rounds.
Beyond computational microscopy by Gleb Novikov
Molecular Dynamics unveils the intricate choreography of biomolecular interactions across different physical landscapes. By integrating the principles of chaos theory with molecular simulations, researchers can better navigate the complex and unpredictable nature of biological systems. In this video blog, a series of showcase animations illustrate how these techniques can be used in drug design and biotechnology, bridging the gap between theoretical science and practical applications.
Cellares Corp.
Cellares (2019, US) is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. Cellares offers:
Cell Shuttleแตแดน, a modular, cGMP platform for industrial scale cell therapy manufacturing (Autologous & Allogeneic, CAR-T, TCR, HSC, NK, TIL, Treg, ฮณฮด T cells). Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation.
On March 12, 2024, Cellares hit manufacturing milestone for its cell therapy factory-in-a-box gaining a current Good Manufacturing Practice (cGMP) stamp of approval for its Cell Shuttle factory-in-a-box, which is the size of a truck and is designed to boost production while reducing costs and failure rates.
Consumable Cartridge, a true end-to-end automation in a closed and automated single-use cartridge. And
Cell Qแตแดน, an automated, high-throughput QC platform for cell therapies.
Cell Qโข integrates the vast majority of typical in-process and release QC assays for cell therapies,
Each Cell Qโข automates the testing of up to 6,000 cell therapy batches per year,
The Cell Qโข includes a set of pre-qualified assays accelerating analytical transfer,
Cell Qโข uses a modular platform that can be expanded to incorporate new instruments providing the flexibility required to meet new IDMO client needs and
High-throughput automation of both manufacturing (Cell Shuttleโข) and QC (Cell Qโข) enables Cellares IDMO to offer up to 10x higher productivity while reducing batch prices by up to 50% compared with conventional CDMOs.
In 2023, Cellares Announced Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellaresโ Technology Adoption Partnership Program (NYSE: BMY) for the manufacture of a CAR-T cell therapy. As part of this expanded agreement, Cellares will optimize, automate and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle.
In January 2024, Cellares launched its second IDMO Smart Factory in Bridgewater, New Jersey, US, for preclinical, clinical and commercial-scale cell therapy manufacturing. The company is headquartered in South San Francisco, California.
On June 27, 2024, Gilead's Kite signed on with Cellares for a cell therapy manufacturing test. Kite Pharma, the Gilead Sciences (NASDAQ: GILD) subsidiary, has agreed to a proof-of-concept evaluation of Cellaresโ Cell Shuttle platform, to determine the viability of the platform as a future manufacturing option for Kite.
The company is backed by world-class investors and has raised over $355M in financing.
Substack Newsletters To Follow in 2024
Money Machine Newsletter. Market beating stocks in 5 min. Picked by elite traders. Delivered weekly to your inbox pre-market. ๐น
Spaero Bio
Spaero (US, 2020) is a developer of a robot-agnostic software system designed to automate experiments and to provide scientists with a fool-proof way to scale automation using liquid handlers already in their lab. Teams can rapidly iterate on complex experiments with ease - ensuring accuracy as protocols and inputs change. The company combines ML, computer vision and lab-automated robots and the founder is Mitch Adler.
Spaero for example, can translate a magnetic bead purification protocol in under 10 minutes by making it easy to translate complex protocols on the liquid handlers already in your lab so teams can generate data faster and keep pace with R&D. Or Spaero can translate a normalization protocol in under 5 minutes.
Spaero Bio has raised $2M by Compound VC and Cantos (for a total of 5 investors):
Cantos VC founded in 2016 is a pre-seed and seed-stage venture capital firm based in San Francisco, California with $55M under management that invests in startups in 'pre-inflection' industries. They focus on the intersection of climate & industrials, the life sciences & AI, aerospace & defense and next-generation computing. They exclusively invest in entrepreneurs building solutions in the real world. The general partner is Ian Rountree and Amee Kapadia is the principal Bio Lead.
Compound VC (New York, 2016) is a New York-based seed fund that invests in startup and early-stage technology companies. They are a team of investors, researchers and operators using their domain expertise, network and prior experiences to help founders solve previously unsolvable technical problems, communicate these breakthroughs to the world and scale commercialization. The managing partner is Michael Dempsey, previously an investment analyst at Crane Partners and a Research & Data Analysis at CB Insights. The founder is David Hirsch. Compound is a research and thesis-driven fund investing in frontier tech across AI/ML, robotics, crypto and bio. They have a public database of areas they are currently tracking and always adding to it.
Transforming patient outcomes with generative AI
AstraZeneca is leveraging generative AI to aid drug discovery and development, particularly in oncology. For this reason, Renee Iacona, Francis Kendall and Sajan Khosla discuss how the technology enhances data analysis, predicts treatment outcomes and streamlines clinical trials.
By combining AI with R (a powerful and widely-used statistical programming language that excels in data analysis and visualization), they can optimize treatment combinations and accelerate drug development.
They are also addressing challenges like data privacy, ethical considerations and the need for skilled talent. This innovative approach wants to deliver better outcomes for patients and push the boundaries of science.
For more about AstraZeneca and AI:
Sakana AI Labs
Sakana AI (2015, Japan) is a Tokyo-based R&D company on a quest to create a new kind of foundational AI model based on nature-inspired intelligence. They developed methods to automatically merge the knowledge of multiple LLMs and they harnessed LLMs to discover new objective functions for tuning other LLMs.
For more about Japan:
They have just introduced The AI Scientist, the first comprehensive system for fully automatic scientific discovery, enabling Foundation Models such as LLMs to perform research independently. In collaboration with the Foerster Lab for AI Research at the University of Oxford and Jeff Clune and Cong Lu at the University of British Columbia, they just released (15 August 2024) their new paper, The AI Scientist: Towards Fully Automated Open-Ended Scientific Discovery for
Proposing and running a fully AI-driven system for automated scientific discovery, applied to ML research.
Automating the entire research lifecycle, from generating novel research ideas, writing any necessary code, and executing experiments, to summarizing experimental results, visualizing them, and presenting its findings in a full scientific manuscript.
Introducing an automated peer review process to evaluate generated papers, write feedback and further improve results, capable of evaluating generated papers with near-human accuracy. And
In this first demonstration, The AI Scientist conducts research in diverse subfields within ML research, discovering novel contributions in popular areas, such as diffusion models, transformers and grokking.
They claim that they can write a paper (from idea implemented to developed into a full paper) for just $15.
Sakana AI, founded by two prominent former Google researchers, raised a total of $130M.
Substack Newsletters To Follow in 2024
AI Startup.Jobs: Twice weekly Artificial Intelligence Startup Jobs mailer. ย ๐ท
Superbio AI Inc
Superbio AI (2021, US) is the world's first no-code AI store for life sciences. Is a secure, no-code and globally-accessible platform hosting cutting-edge tools optimized for ease-of-use and performance, where you can join thousands of scientists and clinicians to use AI for drug discovery, protein design, literature review and more. For example, SearchBio is an AI bot that provides instant access to 200 million articles, delivering concise summaries of studies in seconds.
Another example is CodeBio, an AI chatbot, which can aid with coding-related bioinformatic questions. Both code and explanations are provided in answers, with suggestions for follow-up questions. scGPT (v0.2.1) is a foundation model for single-cell biology, based on generative pre-trained transformers trained on a vast repository of over 33 million cells. The scGPT model demonstrates the ability to extract valuable biological insights and can be further optimized through transfer learning for various downstream applications, including cell-type annotation, multi-batch integration, genetic perturbation prediction and gene network inference. Finally, RFdiffusion is a DL framework that refines the RoseTTAFold structure prediction network. This innovative model excels in diverse protein design challenges, including de novo binding, higher-order symmetry and enzyme active site scaffolding. RFdiffusion's success lies in its ability to generate complex, functional proteins from basic molecular specifications, showcasing its versatility through experimental validations of hundreds of new designs. This marks a significant advancement in protein design using DL, overcoming previous limitations in modeling protein backbone geometry and sequence-structure relationships.
On June 24, 2024, Superbio AI announced that it has entered into an initiative with Memorial Sloan Kettering Cancer Center to make user-friendly biomedical AI available for providers, researchers, and drug developers working to advance the standard of care (Superbio AI Announces Initiative with Leading Global Cancer Center to Provide Access to User-Friendly Biomedical AI via the Superbio Marketplace).
Under this initiative, Superbio AIโs proprietary software platform will be utilized to deploy advanced AI/ML technologies, making them accessible to scientist and physician end-users working on evaluating drug efficacy in the context of clinical trials.
Substack Newsletters To Follow in 2024
Humanity Redefined sheds light on the bleeding edge of technology and how advancements in AI, robotics, and biotech can usher in abundance, expand humanity's horizons, and redefine what it means to be human.
Collaborative Drug Discovery (CDDVault)
CDD Vault (2004), is a cloud based data management platform developed by Collaborative Drug Discovery, Inc (CDD) for securely managing and sharing biological and chemical data, including small molecules, nucleotides, proteins, cells and even mixtures. The CDD software company founded in 2004 as a spin-out of Eli Lilly and Company (NYSE:ย LLY) by Barry Bunin, PhD, utilizes its web-based database solution for managing drug discovery data, primarily through the CDD Vault product which is focused around small molecules and associated bio-assay data.
CDD Vault contains several modules for collaborative project teams to manage, analyze, and share both private & public data: Registration (Chemical registration system), Activity (Experimental data), Visualization (Scientific visualization), Assays (Bioinformatics), Electronic lab notebook, Inventory management software, Curve fitting, AI in pharmacy, API/Data mapping and Chemical database.
On September 13, 2013, Torxยฎ Software Limited announced a collaboration with CDD Vault to facilitate the seamless synthesis and registration of new compounds during the small-molecule drug discovery process (Torxยฎ Software announces global drug discovery collaboration with CDD Vaultยฎ). Torx is a cloud-based platform which enables chemistry teams to collaborate, design molecules and track compound synthesis across the design-make-test-analyze (DMTA) cycle. The optional integration of Torx and CDD Vault creates an automated, shared digital ecosystem and enables rapid transfer of data between platforms and allows users to access the information they need without switching context.
On August 16, 2024, CDDVault and Enamine announced that CDDVault now includes the complete compound collection of Enamine within its AI module for structural similarity searches (CDD Vault Integrates Enamine Compound Collection into AI-Powered Structural Similarity Searches). Enamine, recognized for synthesizing the world's largest and most diverse collections of small molecules, enables โSAR by catalogโ to CDD Vaultโs ultra-fast deep learning structural similarity search functionality. This vast database, now accessible within CDD Vault, enables researchers to explore over 4.3 million compounds in stock at Enamine, optimizing their search for novel drug candidates with unparalleled speed and accuracy.
Finally on June 17, 2024, CDD announced the integration of iChemLabs' industry-leading IUPAC naming technologies into CDD Vault. This integration is facilitated through the licensing of the ChemDoodle Java Application Programming Interface (API), enhancing CDD Vault's capabilities in cheminformatics and chemical structure analysis (Collaborative Drug Discovery (CDD) Includes Industry-Leading IUPAC Naming Technologies From iChemLabs Directly Within CDD Vault). The ChemDoodle API is the core intelligence technology powering the popular ChemDoodle 2D and ChemDoodle 3D desktop applications, used by thousands of institutions in over 100 countries.
Hi Marina, thanks for your work.
Did you check this news from IpA?
https://ir.ipatherapeutics.com/news/news-releases/news-details/2024/ImmunoPrecise-Antibodies-Successfully-Engineers-in-silico-Antibodies-to-Elusive-Tumor-Protein-Using-Its-Patented-LENSai-Technology/default.aspx
100% computer generated without prior knowledge. Boom